No Data
No Data
Integral Diagnostics Upgraded to Buy From Overweight by Jarden
Integral Diagnostics Limited's (ASX:IDX) Market Cap Touched AU$695m Last Week, Benefiting Both Retail Investors Who Own 42% as Well as Institutions
Integral Diagnostics Price Target Raised 10% to A$3.30/Share by Ord Minnett
Ord Minnett Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)
Australian Healthcare Players See Wage Indexation Benefits, Margin Expansion in Fiscal 2025, Jarden Research Says
AU Evening Wrap | ASX Surpasses 8200 as Fed Cuts Rates; BHP Rallies on Morgan Stanley Buy Rating
No Data
No Data